Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Operating Leases (2020 - 2025)

Gain Therapeutics has reported Operating Leases over the past 6 years, most recently at $65026.0 for Q3 2025.

  • Quarterly results put Operating Leases at $65026.0 for Q3 2025, down 32.42% from a year ago — trailing twelve months through Sep 2025 was $65026.0 (down 32.42% YoY), and the annual figure for FY2024 was $53598.0, down 76.68%.
  • Operating Leases for Q3 2025 was $65026.0 at Gain Therapeutics, down from $92851.0 in the prior quarter.
  • Over the last five years, Operating Leases for GANX hit a ceiling of $695053.0 in Q4 2021 and a floor of $30589.0 in Q1 2025.
  • Median Operating Leases over the past 5 years was $330071.0 (2023), compared with a mean of $327370.9.
  • Biggest five-year swings in Operating Leases: surged 73.62% in 2021 and later plummeted 82.75% in 2025.
  • Gain Therapeutics' Operating Leases stood at $695053.0 in 2021, then crashed by 36.44% to $441784.0 in 2022, then tumbled by 47.97% to $229855.0 in 2023, then plummeted by 76.68% to $53598.0 in 2024, then increased by 21.32% to $65026.0 in 2025.
  • The last three reported values for Operating Leases were $65026.0 (Q3 2025), $92851.0 (Q2 2025), and $30589.0 (Q1 2025) per Business Quant data.